<DOC>
	<DOC>NCT00171990</DOC>
	<brief_summary>This is a phase III, multicenter, randomized, double-blind, parallel-group study to compare the efficacy and safety of a two-day treatment with famciclovir (500 mg loading dose followed by 250 mg 12-hourly) to standard five-day treatment with famciclovir (125 mg 12-hourly) in patients with active recurrent genital herpes. This study is not recruiting patients in the United States.</brief_summary>
	<brief_title>Efficacy and Safety of Oral Famciclovir in Patients With Active Recurrent Genital Herpes</brief_title>
	<detailed_description />
	<mesh_term>Herpes Genitalis</mesh_term>
	<mesh_term>Famciclovir</mesh_term>
	<mesh_term>2-Aminopurine</mesh_term>
	<criteria>Diagnosis of genital herpes Had at least 2 recurrences in past 12 months or 1 recurrence in past 6 months Currently taking suppressive herpes antiviral therapy Females who are pregnant, breast feeding or planning to become pregnant during study History of allergy to famciclovir or similar products (e.g. aciclovir, valaciclovir) Other protocoldefined exclusion criteria may apply.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2013</verification_date>
	<keyword>genital herpes</keyword>
	<keyword>herpes</keyword>
	<keyword>famciclovir</keyword>
</DOC>